SchweckendiekW. [Treatment of psoriasis vulgaris]. Med Monatsschr1959; 13(2): 103–104.
2.
GoldRKapposLArnoldDL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367(12): 1098–1107.
3.
FoxRJChanAGoldR, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS patient management considerations. Neurol Clin Pract2016; 6(3): 220–229.
4.
NaismithRTWolinskyJSWundesA, et al. Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler J2019; 26(13): 1729–1739.
5.
NaismithRTWundesAZiemssenT, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing–remitting multiple sclerosis: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs2020; 34(2): 185–196.
6.
SchneiderMKramerJBanksA, et al. New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series. Mult Scler J2024; 30(10): 1382–1385.
